Abstract-Abdominal aortic aneurysm (AAA) is a common vascular degenerative disease. PARP-1 (poly [ADP-ribose] polymerase 1) is a nuclear enzyme, which plays a critical role in vascular diseases. We hypothesized that PARP-1 inhibition might have protective effects on AAA. In vivo, Ang II (angiotensin II) was continuously infused by a micropump for 28 days to induce AAA in mice. In vitro, aortic endothelial cells and smooth muscle cells were stimulated by Ang II for 24 hours. Ang II infusion increased PARP-1 expression and activity and successfully induced AAA formation partly with a hemorrhage in ApoE −/− mice. Genetic deletion of PARP-1 markedly reduced the AAA incidence, abdominal aortic diameter, macrophage infiltration, ICAM-1 (intercellular adhesion molecule 1) and VCAM-1 (vascular adhesion molecule 1) expression, and MMP (matrix metalloproteinase) expression, as well as MMP activity; but increased smooth muscle cells content and collagens expression in AAA. PARP-1 inhibition by PJ-34 also exerted a protective effect on AAA in mice. In aortic endothelial cells, Ang II-induced oxidative stress and DNA damage, resulting in increased PARP-1 expression and activity. Compared with the control, Ang II increased TNF-α (tumor necrosis factor α) and IL-6 (interleukin-6) secretions, ICAM-1 expression and THP-1 (human acute monocytic leukemia cell line) cells adhesion, while PARP-1 inhibition by siRNA reduced the inflammatory response probably through inhibition of the phosphorylation of ERK (extracellular signal-regulated kinase), NF-κB (nuclear factor-κB), and Akt signaling pathways. In smooth muscle cells, Ang II promoted cell migration, proliferation, and apoptosis, reduced collagens expression, but increased MMPs expression, while PARP-1 deletion alleviated these effects partly by reducing NF-κB-targeted MMP-9 expression. PARP-1 inhibition might be a feasible strategy for the treatment of AAA.
A bdominal aortic aneurysm (AAA) is an age-related degenerative disease, which predominantly affects elderly men and leads to a sudden death. [1] [2] [3] Histologically, AAA is characterized by adventitial and medial cell infiltration of lymphocytes and macrophages, destruction of the ECM (extracellular matrix), and neovascularization. 4 Unfortunately, the pathogenesis of AAA remains poorly understood. At present, drug treatments of AAA are lacking, and surgery is the only widely used therapy for this disease. 1, 5 Extensive research is required to develop novel pharmaceutical therapies for AAA.
Previous studies have demonstrated that inflammatory cells percolate through all layers of aneurysmal segments and secrete various inflammatory factors, including cytokines, chemokines, reactive oxygen species, and immunoglobulins. 6, 7 They also release active proteases, such as MMP (matrix metalloproteinase)-9, 8 which can degrade the ECM and may contribute to tissue destruction and weakened arterial wall. 9, 10 Experimental evidence has showed that inhibition of inflammation and MMP activity may attenuate aneurysm formation in animal models. 11 PARP-1 (poly[ADP-ribose] polymerase 1) is a nuclear enzyme that is activated by DNA damage and facilitates DNA repair. 12 PARP-1 consumes nicotinamide adenine dinucleotide to catalyze the addition of PAR (ADP-ribose polymers) to their target proteins, which can modify their functions, interactions, or subcellular localization. 13 A wealth of studies has documented that the transcriptional activation constitutes the primary mode of PARP-1 in modulating gene expression.
14 PARylation by PARP-1 mediates the relaxation of the chromatin superstructure and then facilitates the recruitment of transcription machinery to the promoters or enhancers of target genes. 15 In addition, PARP-1 is involved in the regulation of key transcription factors, such as NF-κB (nuclear factor-κB), AP-1 (activator protein 1), and HSF1 (heat-shock factor protein 1) to regulate gene expression, including ICAM-1 (intercellular adhesion molecule 1), iNOS (inducible nitric oxide synthase), and various cytokines and chemokines, and exerts a profound inflammatory response. [16] [17] [18] A large number of studies have well addressed the involvement of PARP-1 activation in inflammatory disorders, such as myocardial reperfusion injury, stroke, and shock. [19] [20] [21] However, it remains unknown whether PARP-1 inhibition is able to prevent Ang II (angiotensin II)-induced AAA and, if it is so, what mechanisms may underlie this therapeutic approach.
Based on the knowledge mentioned above, we hypothesized that inflammation might induce PARP-1 activation and inhibition of PARP-1 might suppress inflammatory response to prevent AAA formation. Thus, we sought to explore the therapeutic effects of PARP-1 inhibition on Ang II-induced AAA in gene knockout mice and elaborate the possible mechanisms mediating these effects.
Methods
The authors declare that all supporting data are available within the article and its online-only Data Supplement. Detailed material and methods are available in the online-only Data Supplement.
Animals
Animal experiments were approved by ethics committee of Shandong University and performed in compliance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publication Number. 85-23, revised 1985) . ApoE −/− and PARP-1 −/− mice (Jackson Laboratories, Bar Harbor, ME) were housed in a pathogen-free animal care facility on a 12-hour light/12-hour dark cycle and allowed full access to standard mouse chow and water. ApoE −/− /PARP-1 −/− mice were generated by crossing the offspring of ApoE +/− /PARP-1 +/− mice that resulted from mating their respective homozygous knockouts and were genotyped by polymerase chain reaction ( Figure S1 in the online-only Data Supplement).
In the first part of in vivo study, the ApoE −/− mice were randomly divided into the control group and the Ang II group, whereas the ApoE −/− /PARP-1 −/− mice were randomly divided into the PARP-1 −/− group and the Ang II+PARP-1 −/− group (male, 10 weeks old; n=20 per group). The control and PARP-1 −/− group received continuous subcutaneous infusion of saline, while the Ang II and Ang II+PARP-1 −/− group received continuous subcutaneous infusion of Ang II (1000 ng/ kg per minute) via an osmotic pump for 28 days. 22 In the second part of in vivo study, the ApoE −/− mice were randomly divided into the Ang II group and the Ang II+PJ34 group (male, 10 weeks old; n=20 per group). PARP-1 was inhibited by 10 mg/kg PJ34, administered orally via gavage once daily as previously described. 23 After 28 days of infusion, all mice were sacrificed with intraperitoneal injection of ketamine/xylazine solution (80:8 mg/kg), and their aortic tissues were removed for further analysis.
Statistical Analysis
Statistical analysis involved use of SPSS v13.0 (SPSS Inc, Chicago, IL). Data are shown as means±SD. Statistical evaluation was carried out by Student t test between 2 groups and by 1-way ANOVA followed by post hoc within multiple groups. P<0.05 was considered statistically significant.
Results

Heart Rates and Systolic Blood Pressures
In the experiment, the heart rates and systolic blood pressures (SBPs) were measured in mice. There was no difference in the heart rates and SBPs at baseline in mice, whereas SBPs were significantly increased in the Ang II-infused mice in comparison with the control group, and PARP-1 deletion or inhibition had no effect on SBPs (Table S2) .
Ang II Infusion Increased PARP-1 Expression and Activity
We investigated the PARP-1 expression and activity in aortic abdominal aneurysm in Ang II-stimulated mice. As expected, compared with the control group, PARP-1 expression was significantly increased in both mRNA and protein levels, and PARP-1 activity also showed a similar pattern after Ang II infusion ( Figure S2 ).
PARP-1 Deletion Attenuated Ang II-Induced AAA in Mice
Then in the following experiment, the aortic segments from the aortic arch to the bifurcation of common iliac arteries were examined pathologically after Ang II infusion for 28 days. The incidence of AAA was 0% in the control group, 80% in the Ang II group, 0% in the PARP-1 −/− group, and 20% in the Ang II+PARP-1 −/− group. Ang II stimulation could successfully induce AAA formation in mice, mainly developed from the diaphragm to the renal arteries and with a hemorrhage in AAA sometimes, while PARP-1 gene knockout markedly reduced the incidence of AAA in the Ang II+PARP-1 −/− group compared with the Ang II group ( Figure 1A and 1B) . In addition, the H&E staining showed that compared with the control group, Ang II infusion significantly increased the aortic diameter and wall thickness, while PARP-1 deletion reduced it ( Figure 1C and 1D ).
PARP-1 Deletion Increased Smooth Muscle Cell Component and Reduced Inflammatory Cells Infiltration
After Ang II infusion, the masson staining showed the formation of AAA and intraluminal thrombus in Ang II group, while there was only an increase of the abdominal aortic diameter and wall in Ang II+PARP-1 −/− group (Figure 2A ). Then the expression of smooth muscle cells (SMCs) and macrophages was assessed by immunohistochemistry. Figure 2A and 2B showed that Ang II infusion reduced SMCs in the abdominal aortic wall, but PARP-1 deletion resulted in an increased expression of SMCs in comparison with the Ang II group. In contrast, the content of macrophages was markedly increased in the aortic wall in Ang II group, and PARP-1 knockout could reduce the infiltration of macrophages (Figure 2A and 2C). Immunohistochemistry of CD68 also showed that Ang II infusion increased CD68 expression in AAA, whereas PARP-1 deletion reduced it (Figure 2A and 2D). These results suggested that PARP-1 deletion could protect against Ang II-induced AAA by upregulation of SMCs and reduction of inflammatory cells infiltration.
PARP-1 Deletion Reduced Ang II-Induced ICAM-1 and VCAM-1 Expression In Vivo
As chronic inflammation of the aortic wall is a main feature of AAA, we examined the expression of inflammatory cytokines, such as ICAM-1 and VCAM-1. In mice, as assessed by mRNA, Ang II infusion increased the mRNA expression of ICAM-1 and VCAM-1, while PARP-1 deletion reduced it ( Figure S3A and S3B). Meanwhile, the Western blotting analysis showed that compared with the control, Ang II increased the protein expression of ICAM-1 and VCAM-1, and PARP-1 deletion could reduce Ang II-induced the upregulation of ICAM-1 and VCAM-1 ( Figure 3A ).
PARP-1 Deletion Increased Collagens but Reduced MMPs Expression and Activity In Vivo
After Ang II infusion for 28 days, the mRNA and protein expression of collagens and MMPs were analyzed in vivo. The real time-polymerase chain reaction showed that, compared with the control, Ang II reduced collagen І and collagen III mRNA expression, but increased the mRNA expression of MMP-2 and MMP-9, while PARP-1 gene deletion could significantly alleviate the effect ( Figure S3C through S3F). The Western blotting analysis showed a similar result ( Figure 3B and 3C). What is more, in situ zymography showed that Ang II infusion increased the activity of MMPs, whereas PARP-1 deletion could reduce it ( Figure 3D ).
Ang II-Induced Oxidative Stress and DNA Damage In Vitro
DNA damage was assessed by the 8-hydroxydeoxyguanosine assay in aortic endothelial cells, which is a marker of oxidative stress-derived DNA damage. As shown in Figure 4A , compared with the control, Ang II stimulation increased the expression of 8-hydroxydeoxyguanosine, which suggested that Ang II could induce DNA damage. Then we investigated the mechanism. The thiobarbituric acid assay showed that Ang II stimulation increased malondialdehyde content ( Figure 4B ), and the dihydroethidium staining showed that Ang II increased reactive oxygen species (ROS) production ( Figure 4C ), which suggested that Ang II could induce DNA damage by induction of reactive nitrogen species and ROS. As a result, PARP-1 expression and activity were subsequently upregulated after Ang II stimulation in vitro ( Figure S4 ).
PARP-1 Inhibition Reduced Ang II-Induced Inflammatory Response In Vitro
In aortic endothelial cells, PARP-1 expression was inhibited by PARP-1 siRNA for 24 hours before Ang II. First, we validated the efficient of PARP-1 siRNA. The mRNA and protein expression of PARP-1 was significantly reduced by siRNA, while the negative control of PARP-1 siRNA (si-NC) had no effect ( Figure S5 ). Then we analyzed the TNF-α (tumor necrosis factor α) and IL-6 (interleukin-6) secretions, 
PARP-1 Inhibition Reduced the Activation of ERK, NF-κB, and Akt In Vitro
Then we investigated the underlying mechanism of PARP-1 in Ang II-induced inflammatory response in vitro. After aortic endothelial cells were stimulated by Ang II, we examined the protein expression of phosphorylated ERK 1/2 (extracellular signal-regulated kinase 1/2), NF-κB p65, and Akt.
As compared with the control cells, Ang II stimulation dramatically increased the phosphorylation of ERK 1/2, NF-κB p65, and Akt, while PARP-1 inhibition reduced their phosphorylation ( Figure 5A through 5D ). Then the inhibitors of ERK 1/2 (U0126), NF-κB p65 (BAY11-7082), and Akt (MK2206) were added 1 hour before Ang II in the experiment. The results showed that the inhibitors could reduce Ang II-induced inflammatory response, including TNF-ɑ and IL-6 secretions and THP-1 cell adhesion ( Figure 5E and 5F). Thus, PARP-1 inhibition might reduce Ang II-induced inflammatory response by suppression the phosphorylation of ERK1/2, NF-κB, and Akt pathway.
PARP-1 Deletion Increased Collagens Expression but Reduced MMPs Expression
After SMCs were isolated from mice and stimulated by Ang II, collagens and MMPs expressions were analyzed by Western blotting analysis. Compared with the control, Ang II reduced the protein expression of collagen І and collagen III but increased MMP-2 and MMP-9 protein expression. However, PARP-1 deletion increased collagens expression but reduced MMPs expression ( Figure 6A and 6B).
PARP-1-Regulated MMP-9 Expression by Targeting NF-κB/MMP-9 Axis
Then we investigated the underlying mechanism that PARP-1 inhibition reduced MMPs expression. As shown in Figure 6C , the real time-polymerase chain reaction showed that PARP-1 or NF-κB inhibition could reduce MMP-9 mRNA expression. Using a ChIP assay, we further demonstrated that NF-κB could bind to the MMP-9 promoter. As we expected, PARP-1 or NF-κB inhibition abrogated the increment of luciferase activity induced by Ang II stimulation. The results suggested that PARP-1 might regulate MMP-9 expression by targeting NF-κB/MMP-9 axis. 
PARP-1 Deletion Reduced SMCs Migration, Proliferation, and Apoptosis
SMCs migration was assessed by transwell. Compared with the control, Ang II significantly increased the number of SMCs on the lower surfaces of the transwell inserts, whereas PARP-1 deletion could reduce it ( Figure S7A and S7B). Then SMCs proliferation and apoptosis were assessed after Ang II stimulation. The EdU staining showed that compared with the control, Ang II promoted cell proliferation, while PARP-1 deletion reduced it ( Figure S7C and S7D) . Then cell apoptosis analyzed by TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling) staining showed that PARP-1 deletion could reduce Ang II-induced SMCs apoptosis ( Figure S7E and S7F). Overall, these effects of PARP-1 deletion on SMCs might contribute to reducing AAA formation and diameters.
PARP-1 Inhibition by PJ34 Showed a Protective Effect on AAA Formation
In the end, we investigated the effect of PARP-1 inhibition by PJ34 on AAA formation. Compared with the Ang II, PJ34 reduced the incidence and diameter of AAA. Meanwhile, the immunochemistry showed that PJ34 increased SMC content but reduced MOMA-2 (monocyte+macrophage) and CD68 expression ( Figure S8 ). Further experiments revealed that compared with the Ang II group, PJ34 reduced the expression of ICAM-1 and VCAM-1, increased collagens expression, and reduced MMPs expression and activity, resulting in protection against AAA formation ( Figure S9 ).
Discussion
In the present study, we investigated the role and mechanism of PARP-1 in Ang II-induced AAA in vivo and in vitro. In vivo, we found that PARP-1 gene deletion or inhibition could alleviate or prevent the formation and development of Ang II-induced AAA. In vitro, the protective effect of PARP-1 inhibition was closely associated with the reduction of inflammatory response, macrophages infiltration, and MMPs expression, as well as the upregulation of SMCs and collagen content. This is the first report that reveals a protective effect of PARP-1 inhibition in the development of Ang II-induced AAA, which may provide a therapeutic target for the treatment of AAA in clinic. AAA usually occurs in the infrarenal part of the human aorta, which is generally defined as a maximal aortic diameter of 3 cm, although definitions such as 4 cm and an infrarenal to suprarenal diameter ratio of 1.2 to 1.5 have also been used. 24 It has been demonstrated that PARP-1 inhibition improved the endothelial dysfunction associated with hypertension and aging in rats and atherosclerosis in ApoE (apolipoprotein E) deficient mice. 25, 26 PARP is a downstream nuclear target of Ang IIinduced signaling pathway, contributing to cardiac hypertrophy and failure. 27 These results suggested a probable role of PARP-1 in Ang II-induced AAA. In our experiment, for the first time, we investigated the role of PARP-1 in AAA formation by use of gene knockout mice. As described in previous study, 28 we also successfully induced AAA formation by continuous infusion of Ang II in ApoE −/− mice, with a hemorrhage in some aneurysms. Moreover, we found that Ang II stimulation increased the expression and activity of PARP-1 in mice, which suggested a critical role of PARP-1 in AAA. As expected, PARP-1 gene deletion or inhibition showed a protective effect, with significant reduction of the incidence of AAA and the diameter of aorta.
One important finding of our study was that PARP-1 deletion or inhibition did not affect SBPs in mice. Although Ang II infusion induced a notable elevation of SBP, PARP-1 deletion or inhibition exerted no remarkable effect on SBP, which was similar to previous study that PARP-1 gene deletion normalizes autonomic and vascular dysfunctions in dyslipidemic mice, without affecting baseline heart rate and BP. 29 Thus, we speculated that the protective effect of PARP-1 inhibition on AAA formation was BP independent.
Rather than a simple degenerative process, AAA has proven to be a dynamic remodeling process of the aortic wall, which is closely associated with chronic adventitial and medial inflammatory cell infiltration, elastin fragmentation and degeneration, and medial attenuation. 30, 31 Then we first investigated the role of aortic endothelium in AAA. ROS generation is demonstrated to markedly increase in the aortic aneurysmal tissues. 32 Szabo finds that Ang II triggers DNA breakage and activates PARP via ROS and reactive nitrogen species generation in the vascular endothelium, leading to the development of endothelial dysfunction. 33 PARP-1 inhibition reduces plaque size and promotes plaque stability in ApoE-deficient mice in atherosclerosis. 34 In our vitro study, we also found that Ang II stimulation increased ROS and reactive nitrogen species production as assessed by dihydroethidium and malondialdehyde analysis. 8-Hydroxydeoxyguanosine, a marker of oxidative stress-derived DNA damage, was significantly increased in the Ang II group as compared with the control, resulting in the upregulation of PARP-1 expression and activity as described in previous study. 35 Moreover, in vitro, Ang II increased TNF-α and IL-6 secretions, ICAM-1 protein expression, and THP-1 cells adhesion, but PARP-1 inhibition could reduce the inflammatory response. In vivo, PARP-1 gene deletion also reduced the infiltration of inflammatory cells, the expression of ICAM-1 and VCAM-1. These results suggested a critical role of endothelium in the initiation of AAA, which might induce inflammation and mediate the chemotaxis, adhesion, and infiltration of macrophages after PARP-1 activation.
Various cell signaling transduction molecules were involved in the pathogenesis of AAA. AMPK (AMP-activated protein kinase)-α2 has been demonstrated to instigate nicotine-induced AAA in mice in vivo. 36 ERK1/2, a member of MAP (mitogen-activated protein) kinase family, was closely associated with inflammation and MMP activity. 37 The activation of ERK pathway is required for the induction of TNF-α by lipopolysaccharides. 38 In our experiment, we found that PARP-1 inhibition reduced the phosphorylation of ERK induced by Ang II, and ERK inhibition by U0126 could reduce TNF-α and IL-6 secretions, as well as THP-1 cell adhesion. The transcription factor NF-κB plays a critical role in the regulation of proinflammatory and anti-inflammatory genes. 39 The phosphorylation of NF-κB can increase the ability of banding to its target sites on DNA. 40 PARP-1 inhibition attenuates atherosclerotic plaque formation through inhibition of NF-kB translocation and subsequent expression of inflammatory factors in hyperhomocysteinemic mice. 41 In our experiment, we found that PARP-1 inhibition reduced Ang II-induced NF-κB phosphorylation and NF-κB inhibition by BAY11-7082 reduced inflammatory response. The most interesting part is the role of Akt, which plays a vital role in cell growth, proliferation, energy metabolism, and survival. 42 In the heart, the acute activation of Akt promotes the cardiomyocytes survival and function, 43 while chronic activation can cause cardiac hypertrophy and maladaptive remodeling. 44 Akt2 is demonstrated to confer protection against aortic aneurysms and dissections, 45 whereas Vinexin b deficiency attenuates atherogenesis primarily by suppressing vascular inflammation and inactivating Akt/NF-κB signaling. 46 These results suggest the double-edged role of Akt. In aortic endothelial cells, by use of MK2206, an Akt inhibitor, we found that PARP-1 inhibition reduced Ang II-induced inflammatory response through inhibition of Akt activation. In a word, PARP-1 inhibition significantly reduced Ang II-induced the phosphorylation of ERK1/2, NF-κB, and Akt. The inhibitors of these signaling molecules could reduce the inflammatory response, suggesting that the inhibitory effect of PARP-1 inhibition on inflammation was partly through downregulation Ang II-mediated ERK1/2, NF-κB, and Akt phosphorylation.
Then we shifted our focus on SMCs. Animal and human experiments have revealed a paucity of medial SMCs in AAA. 47, 48 As the medial SMCs are major sources of ECM proteins, depletion of medial SMCs may make an important contribution to aneurysm by inducing aortic medial degeneration and lumen dilatation. In our experiment, as assessed by immunohistochemistry, Ang II-reduced SMCs content in AAA, while PARP-1 deletion increased it in mice. In SMCs, we found that Ang II promoted the migration, increased cell proliferation, and induced cell apoptosis. PARP-1 deletion could suppress cell migration, reduce SMCs proliferation and apoptosis, which might be benefit for maintain and recovery of arterial wall. Arterial wall ECM, the structural framework of the arterial wall, consists of elastins, collagens, and proteoglycans. 49 Collagen (especially types I and III) in the media and adventitia provides tensile strength to the aortic wall. Collagen synthesis increases in the early stage of aneurysm formation, suggesting a repair process. 50 In Ang II-induced hypertension in rats, inhibition of PARP prevents aortic fibrosis by inhibiting TGF (transforming growth factor)-β/Smad3 pathway. 51 However, in later stages, collagen degradation mainly caused by MMPs exceeds its synthesis, ultimately leading to AAA rupture. Proteolytic enzymes, such as MMPs and cysteine protease cathepsins, can degrade ECM and, therefore, lead to AAA formation. 52, 53 Indeed, previous study has shown that AAA exhibit increased local production of enzymes capable of degrading collagen and elastin. 54 As expected, we also found that compared with the control, Ang II reduced the expression of collagens, whereas PARP-1 deletion could increase collagens expression in vivo and vitro. Moreover, Ang II stimulation increased MMP-2 and MMP-9 expression with upregulation of MMPs activity, whereas PARP-1 deletion could reduce MMPs expression and activity. Further experiment uncovered that PARP-1 inhibition attenuated the NF-κB/ MMP-9 axis, which was activated by Ang II stimulation and might be responsible for the collagens destruction.
Interestingly, we observed that the content of SMCs was decreased, while the expression and activity of MMPs were increased in Ang II-induced AAA. We reasoned these possibilities to produce this difference. First, the switch of SMCs phenotype from contractile to synthetic type might play an important role in MMPs activation. Second, both VSMC-and macrophage-derived MMPs are key enzymes in AAA formation. 36 There were 2 potential limitations in our study. First, it is difficult, or even impossible, to obtain human sample, thus we did our experiment only in animal and cells. Second, endothelial cells and SMCs were analyzed in current experiment, and macrophages should be investigated in further experiment.
In conclusion, we found that PARP-1 deletion reduced Ang II-induced AAA incidence and aortic diameter, probably through inhibition of inflammatory response via ERK1/2, NF-κB, and Akt pathway, upregulation of SMCs and collagens, reduction of inflammatory cells infiltration, and downregulation of MMPs expression and activity. Thus, PARP-1 inhibition may provide a novel approach to the treatment of AAA.
Perspectives
Currently, the pathogenesis of AAA remains unclear, and surgical repair is the only choice of treatment in patients with a large AAA, except for asymptomatic patients or those with a small AAA or contraindications for surgery. Thus, a pharmacological approach to AAA is highly warranted. Our results clearly demonstrated that PARP-1 inhibition provided protection against Ang II-induced AAA by inhibition of inflammatory response via ERK1/2, NF-κB, and Akt pathway, reduction of MMPs and macrophages infiltration, and upregulation of SMCs and collagens expression. Thus, PARP-1 inhibition may provide a promising approach to the prevention and treatment of AAA in the future.
